Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 1
2004 2
2008 2
2009 3
2010 2
2011 5
2012 10
2013 6
2014 7
2015 16
2016 13
2017 9
2018 14
2019 12
2020 14
2021 10
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 34949662

104 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Markers for Long-term Survival in Stage IIIA (N2) NSCLC Patients.
Nastase A, Dima SO, Lupo A, Laszlo V, Tagett R, Draghici S, Georgescu ME, Nechifor A, Berbece S, Popescu I, Alifano M, Klepetko W, Grigoroiu M. Nastase A, et al. Cancer Genomics Proteomics. 2022 Jan-Feb;19(1):94-104. doi: 10.21873/cgp.20306. Cancer Genomics Proteomics. 2022. PMID: 34949662 Free PMC article.
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Zhong WZ, et al. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.
104 results